바이오톡스텍

086040KOSDAQ자연과학 및 공학 연구개발업

59.8 / 100

Reference Date: 2026-04-13

Financial Score24.0 / 40

News Sentiment17.8 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioToxtek specializes in non-clinical CRO services, conducting toxicity and safety/efficacy evaluations using rodents and primates for pharmaceuticals, cell therapies, and chemicals. The company actively participates in new material development and is advancing the commercialization of therapeutic candidates like TB-4 and HX-1171 through technology licensing.

Number of Employees

241people

Average Salary

47.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

42.97Industry Average 120.078.0Point

Half of industry avg (excellent)

PBR

1.59Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE

-4.74Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

44.42Industry Average 7.520.0Point

5.9x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲20.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
바이오톡스텍, 지투지바이오에 10억 투자→130억원 수익 ‘잭팟’
바이오톡스텍이 코스닥 상장사 지투지바이오에 투자하여 130억원에 가까운 투자수익을 거두며 '잭팟'을 터뜨렸습니다.
Positive
키프라임리서치, 유럽 바이오테크와 24억원 규모 GLP 수주계약
바이오톡스텍의 자회사 키프라임리서치가 유럽 바이오기업과 24억원 규모의 영장류 GLP 비임상시험 계약을 체결하며 올해 세 번째 해외 GLP 수주를 달성했습니다.
Positive
바이오톡스텍 "키프라임리서치, 유럽서 ADC 비임상 대행 수주"
바이오톡스텍은 자회사 키프라임리서치가 유럽 지역의 ADC 전문 개발기업으로부터 영장류 GLP 비임상시험을 대행하는 계약을 맺었다고 밝혔습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (46%)

Current 3,180Won52-week high 3,92552-week low 2,525

1-month return2.0Point

1m -2.15% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-27
Neutral감사보고서제출2026-03-19
Neutral사업보고서 (2025.12)2026-03-19